20th April 2021

Swansea Bay to support new UK trial for COVID-19 vaccine

Swansea Bay University Health Board and Public Health Wales are looking for volunteers to participate in the latest clinical trial studying a vaccine against COVID-19.

It is the first study to test a plant-derived COVID-19 vaccine candidate, and will evaluate the efficacy and safety of the Coronavirus-Like Particle COVID-19 Vaccine (CoVLP).

The vaccine has already been through early phase human studies and now requires testing on a large scale and a study involving 1,500 people across the UK is starting. The aim is to recruit volunteers between 18 – 39 years old and who live in Swansea and the local areas.

The study will involve volunteers making a maximum of 10 visits to the study site over approximately 26 months. Reasonable travel expenses will be reimbursed and volunteers will receive payment for participating in this study.

The Medicago vaccine study will run across fourteen sites in the United Kingdom, in addition to multiple sites in the United States, Canada, Europe and Latin America. The study will enrol up to 30,000 volunteers worldwide.

Dr Brendan Healy, Principal Investigator for the Medicago trial and Consultant in Microbiology and Infectious Diseases at Public Health Wales, said: “We are all now starting to see the beneficial effects of COVID-19 vaccinations. Whilst it is encouraging that we already have access to three vaccines in the UK it is very important that we continue to develop vaccines so there is greater choice and an ability to select vaccines based on their individual benefits. Medicago’s plant-derived COVID-19 vaccine has already been through early phase human studies. I am delighted Swansea Bay will be recruiting in partnership with Public Health Wales into the next phase of this vaccine’s development. I would like to encourage people living in the Swansea Bay and the surrounding areas to consider taking part.”

Interested individuals are invited to sign up to the trial website here